New radiotracer aims to spot hidden cancers
NCT ID NCT07400263
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new radioactive tracer called [68Ga]Ga-PN-EpC1 for PET/CT scans in 30 people with suspected or confirmed epithelial tumors. The tracer targets a protein called EpCAM found on many cancer cells. Researchers want to see if it can find tumors more accurately than standard imaging, and if it's safe. Participants get one injection before their planned biopsy or surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [68Ga]Ga-PN-EpC1 radiotracer
- What this could lead to
- If successful, this could lead to a more accurate imaging method for detecting epithelial cancers, helping doctors see tumors that other scans might miss.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The radiotracer may not work well for all tumor types or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.